Palantir and Dewpoint Therapeutics Announce Strategic Partnership

Rhea-AI Summary

Palantir Technologies (NYSE: PLTR) has entered a multi-year partnership with Dewpoint Therapeutics to enhance drug discovery using its Foundry platform. This collaboration will allow Dewpoint to analyze various data sources, including lab results and published literature, to identify new therapeutic compounds. Foundry will serve as Dewpoint's centralized knowledge repository, facilitating data-driven decisions in their research. This agreement highlights Palantir's commitment to the biotechnology sector, integrating advanced analytics to support drug development efforts.

Positive

• Multi-year partnership with Dewpoint Therapeutics enhances Palantir's presence in biotechnology.
• Foundry platform enables improved drug discovery through comprehensive data analysis.
• Collaboration supports advancements in treatments for serious diseases.

Negative

• None.

DENVER & BOSTON--(BUSINESS WIRE)-- Palantir Technologies Inc. (NYSE: PLTR), a leading builder of operating systems for the modern enterprise, and Dewpoint Therapeutics (“Dewpoint"), the leading biomolecular condensates company, today announced a partnership for Palantir’s Foundry platform to help power Dewpoint’s efforts to discover treatments and cures for the most challenging diseases.

Palantir Foundry will help to enable researchers at Dewpoint to further their understanding of condensates biology by analyzing lab data along with other data sources, including data from the published literature and databases, to identify new compounds and therapeutic approaches.

Dewpoint will also use Foundry as the primary platform for its centralized knowledge repository, helping it contextualize its experimental results and prioritize the most viable outcomes. This multi-year agreement marks one of Palantir’s most comprehensive partnerships with a biotechnology company.

Palantir Foundry is designed to integrate disparate and siloed information sources to lead to data-driven analysis and decision making. It allows users to track lineage across systems, making it particularly suited for work in life sciences and the biotechnology sector, where data sources come from several unique and separate systems.

At Dewpoint, Foundry will be able to work seamlessly with the existing systems in its laboratories to provide researchers with a comprehensive foundation for exploration and analysis.

“We think Dewpoint is changing the way the world approaches drug design by exploring new frontiers of disease biology, requiring a game changing solution that goes beyond just cloud and infrastructure to drive their R&D and scale with their vision as they grow,” said Lalarukh Haris Shaikh, Palantir’s Head of Biotech. “We are proud to partner with Dewpoint and share their passion of working on one of the most exciting translational medicine approaches of our time.”

Foundry will help researchers make decisions around compound and target viability and streamline experiments and automate analysis by creating a digital twin of the research environment. One concrete example of Foundry’s use at Dewpoint Therapeutics is the expansion of the data foundation to include advanced genetic analysis for disease association and correlation with condensate content, empowering future discoveries.

“Key to our approach has been creating a seamless connection between our wet-lab and dry-lab capabilities, with machine learning and AI at the center. Foundry has provided us with a solid foundation for us to fully connect and operationalize our entire lab to enterprise and enable the discovery and development of new drugs,” said Dewpoint CEO Ameet Nathwani.

About Biomolecular Condensates

Biomolecular condensates, formed through a process called phase separation, are membraneless droplets inside cells that facilitate molecular interactions and help cells perform vital functions. Condensates have been shown to play a critical role in key biological processes and in serious, intractable diseases across areas including neurodegeneration, cancer, inflammation, infectious disease, metabolic disease, and rare genetic disorders. The first condensates were observed more than 100 years ago. It is only in the last dozen years, though, that scientists—including Dewpoint founders Tony Hyman of the Max Planck Institute in Dresden and Rick Young of the Whitehead Institute—have begun to understand the dynamic nature and function of condensates. Dewpoint develops drugs that exploit this biology.

About Dewpoint Therapeutics

Dewpoint Therapeutics is the first company to apply the emerging understanding of biomolecular condensates to drug discovery. Dewpoint believes that a vast range of conditions have pathways that are regulated by condensates or arise from the dysfunction of condensates — including cancer, neurodegeneration, infectious disease, and metabolic disease. Dewpoint scientists work in Boston, Dresden, and Berlin to translate condensate biology into treatments for the toughest diseases. Learn more at dewpointx.com, and follow us on Twitter and LinkedIn.

About Palantir Technologies Inc.

Palantir Technologies Inc. builds and deploys operating systems for the modern enterprise. Additional information is available at https://www.palantir.com.

Who dares, wins.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These statements may relate to, but are not limited to, Palantir’s expectations regarding the terms of the partnership and the expected benefits of our software platforms. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. Forward-looking statements are based on information available at the time those statements are made and were based on current expectations as well as the beliefs and assumptions of management as of that time with respect to future events. These statements are subject to risks and uncertainties, many of which involve factors or circumstances that are beyond our control. These risks and uncertainties include our ability to meet the unique needs of our customer; the failure of our platforms to satisfy our customer or perform as desired; the frequency or severity of any software and implementation errors; our platforms’ reliability; and our customer’s ability to modify or terminate the partnership. Additional information regarding these and other risks and uncertainties is included in the filings we make with the Securities and Exchange Commission from time to time. Except as required by law, we do not undertake any obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future developments, or otherwise.

View source version on businesswire.com: https://www.businesswire.com/news/home/20211220005196/en/

Lisa Gordon

media@palantir.com

Source: Palantir Technologies Inc.

FAQ

What is the partnership between Palantir and Dewpoint Technologies about?

Palantir's partnership with Dewpoint involves using the Foundry platform to enhance drug discovery by analyzing diverse data sources.

How will Foundry benefit Dewpoint Therapeutics?

Foundry will help Dewpoint by providing a centralized knowledge repository, allowing better contextualization of experimental results and decision-making in drug discovery.

What diseases is Dewpoint targeting with its research?

Dewpoint focuses on diseases related to biomolecular condensates, including cancer, neurodegeneration, inflammation, and rare genetic disorders.

When was the partnership between Palantir and Dewpoint announced?

The partnership was announced on the date of the press release, indicating a significant collaboration in drug discovery.

What role does Palantir Foundry play in biomedical research?

Palantir Foundry integrates various data sources for data-driven analysis, aiding researchers in making informed decisions about drug development.